Oppenheimer lowered the firm’s price target on Insulet (PODD) to $300 from $365 and keeps an Outperform rating on the shares following quarterly results. The firm is adjusting estimates for Q4 and FY26 guidance, and it is introducing FY27 estimates.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PODD: